Phathom Pharmaceuticals, Inc.PHATEarnings & Financial Report
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.
PHAT Q4 FY2025 Key Financial Metrics
Revenue
$57.6M
Gross Profit
$49.9M
Operating Profit
N/A
Net Profit
N/A
Gross Margin
86.7%
Operating Margin
N/A
Net Margin
N/A
YoY Growth
94.1%
Phathom Pharmaceuticals, Inc. Q4 FY2025 Financial Summary
Phathom Pharmaceuticals, Inc. reported revenue of $57.6M (up 94.1% YoY) for Q4 FY2025, with a net profit of N/A (up 71.6% YoY) (N/A margin). Cost of goods sold was $7.6M.
Key Financial Metrics
| Total Revenue | $57.6M |
|---|---|
| Net Profit | N/A |
| Gross Margin | 86.7% |
| Operating Margin | N/A |
| Report Period | Q4 FY2025 |
Phathom Pharmaceuticals, Inc. Annual Revenue by Year
Phathom Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $175.1M).
Phathom Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Phathom Pharmaceuticals, Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $57.6M | +94.1% | N/A | N/A |
| Q3 FY2025 | $49.5M | +202.7% | $-30.0M | -60.5% |
| Q2 FY2025 | $39.5M | +439.4% | $-75.8M | -191.9% |
| Q1 FY2025 | $28.5M | +1391.6% | $-94.3M | -330.7% |
| Q4 FY2024 | $29.7M | +4249.6% | N/A | N/A |
| Q3 FY2024 | $16.4M | — | $-85.6M | -523.3% |
| Q2 FY2024 | $7.3M | — | $-91.4M | -1248.6% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $16.4M | $29.7M | $28.5M | $39.5M | $49.5M | $57.6M |
| YoY Growth | N/A | N/A | 4249.6% | 1391.6% | 439.4% | 202.7% | 94.1% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Assets | $319.4M | $387.0M | $378.3M | $294.2M | $250.2M | $240.3M | $259.1M |
| Liabilities | $553.2M | $574.2M | $631.9M | $632.6M | $656.1M | $662.8M | $697.3M |
| Equity | $-233.8M | $-187.1M | $-253.6M | $-338.4M | $-405.8M | $-422.5M | $-438.2M |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-70.7M | $-63.6M | $-266.8M | $-84.9M | $-62.7M | $-14.1M | $-166.8M |